Most Recent
A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.
The Australian Competition and Consumer Commission has signed off on pharmaceutical giant GlaxoSmithKline’s proposed acquisition of fellow heavyweight Pfizer, a merger which will put pain medications Panadol, Voltaren and Advil all under one roof, with the competition cop saying Nurofen maker Reckitt will still be able to compete.
Israeli drug maker Teva has won its bid for communications between Germany-based Boehringer and capsule manufacturers to help prove its claim that a patent at the centre of a dispute over the top-selling inhaler Spiriva was invalid for obviousness.
Drug maker Janssen will drop its long-running patent lawsuit against Alphapharm after the generic drug maker agreed to refrain from making products that allegedly infringe Janssen's patents for its HIV drug Prezista.
A judge has signed off on the lead applicants' bid to expand the current group definition in a class action against Johnson & Johnson unit Ethicon over allegedly defective vaginal mesh products, saying there was "no reason in logic" why the request should be denied.
German medical device company B. Braun Melsungen has dropped its appeal of a ruling invalidating three of its intravenous catheter patents and finding rival Becton Dickinson did not infringe the patents.
After losing its fight for a temporary injunction, Sanofi-Aventis has dropped its patent lawsuit against Alphapharm over the generic drug maker's plans to market a competing insulin injector pen in Australia.
A judge has refused an application by generic drug maker Juno Pharmacueticals to withdraw an admission in a battle with Millennium Pharmaceuticals over its cheap version of breakthrough cancer drug Velcade, denying Juno a potential defence to allegations of patent infringement.
Horse vaccine maker Zoetis has appealed a ruling that denied its request for $450,000 as security for costs in an unfunded class action accusing it of failing to warn about the vaccine's side effects.
The founder and former CEO of Smiles Inclusive has been taken to court by the dental company, which accuses him of serious misconduct over allegedly unlawful payments and transactions.